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S40 Journal of Thoracic Oncology Vol. 11 No. 2Sand survival in lung cancer patients. The SNP, which
arose in Africa, modulates the splicing of MRPL43,
leading to a linear decrease in the major isoform and a
switch in the balance of oxidative phosphorylation and
glycolysis. Our work identiﬁes a new pathway of po-
tential relevance to lung cancer and provides new
insight into the role of mitochondrial ribosomes in
cancer.
Prognostic nomogram for predicting
survival of non-small-cell lung cancer
patients*
Jeong Seon Ryu, Bo-Rim Yi, Jung Soo Kim Inha
University Hospital, Incheon, Incheon, KoreaA few prognostic factors have been widely accepted in
non-small-cell lung cancer (NSCLC). Nomogram is a
useful tool of providing more accurate prognostic in-
formation in cancer patients. For the ﬁrst time, we tried
to develop prognostic nomogram for patients with stage
III/IV non-small-cell lung cancer (NSCLC) who seek
medical care in daily clinical practices.
Using the 15 pretreatment readily available clinical
variables in 752 patients with stage III/IV NSCLC, we
performed a Cox proportional hazard analysis with hi-
erarchical backward elimination methods to identify
survival prognostic factors. Then using these indepen-
dent prognostic factors, the prognostic nomogram was
constructed from data collected from a test group of 376
(50%) randomly sampled patients with NSCLC and it
was validated with data from the remaining 50% of the
patients.
The independent poor prognostic factors that were
included in the nomogram are as follows: male, weight
loss of more than 5%, Eastern Cooperative Oncology
Group performance status greater than 1, histology of no
squamous cell carcinoma, Tumor-Node-Metastasis stage
greater than IIIA, increased serum calcium, low serum
hemoglobin, and no chemotherapy. The prognostic
nomogram constructed from eight independent prog-
nostic factors predicted survival well with a concordance
index of 0.66, which was validated by an internal group
of patients.
We developed a unique prognostic nomogram con-
structed using pretreatment readily available clinical
variables to predict the probability of survival in NSCLC
patients. This prognostic nomogram may help re-
searchers in designing randomized clinical trials as well
as assist clinicians in selecting the most appropriate
therapy for NSCLC patients.* Due to unforeseen circumstance, this poster was not presented.High expression of endoplasmic
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Various conditions such as low oxygen and low
nutrition cause accumulation of unfolded or misfolded
proteins in the endoplasmic reticulum (ER), leading to
ER stress. To overcome this, cells have resistance
mechanisms called unfolded protein response (UPR).
When UPR is insufﬁcient, ER-mediated apoptosis oc-
curs. Recent reports have shown that several diseases
including cancers can be caused by ER stress. In
cancers, high proliferation rates and the presence of
mutated gene products lead to accumulation of
unfolded and misfolded proteins in the ER and adap-
tation to ER stress is essential for survival of cancer
cells.
As preliminary analysis, we used publicly available
expression proﬁles (GSE10245 and normal tissue
data sets) and analyzed expression levels of 84 ER
stress pathway genes. We found ER oxidoreductin 1L
(ERO1L) was highly expressed in many types of
cancer tissue, while expression was low in normal
tissues. In addition, using OncomineTM, we found
ERO1L high expression was associated with poor
prognosis of non-small cell lung cancer. There are
some reports that expression of ERO1L is beneﬁcial
to tumor cells, but association with lung cancer has
not been reported. Therefore , we sought to deter-
mine the role of ERO1L in lung cancer, including
response to therapy.
Using quantitative RT-PCR and Western blotting, we
identiﬁed NCI-H441, HCC2935, and NCI-H2347 as
ERO1L high expression cell lines. NCI-H520, NCI-
H522, and SK-LU-1 were ERO1L low expression cell
lines. We then exposed these cells to cisplatin (CDDP)
and determined the half maximal inhibitory concen-
tration (IC50). IC50 values for CDDP was 91, 64, and
21 mM, respectively, in cells with high ERO1L
expression. IC50 values for CDDP was 2.6, 4.1, and 22
mM, respectively, in cells with low ERO1L expression.
We then exposed cell lines to both CDDP and EN460,
an ERO1L inhibitor. When CDDP was combined with
low dose EN460 (1/10 of IC50), there was a trend
toward decreased IC50 for CDDP. We also evaluated
IC50 values for CDDP plus high dose EN460 (1/3 of
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CDDP. In summary, high ERO1L expression was
associated with poor prognosis of non-small cell lung
cancer and resistance to CDDP therapy, which may be
ameliorated with addition of EN460. These data
suggest that ERO1L may promote lung cancer cell
survival and resistance to chemotherapy by reduction
of ER stress, and that ERO1L inhibitor may sensitize
CDDP-resistant cancer cells to CDDP.
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Recent studies reveal responses in approximately 20% of
non-small cell lung cancer (NSCLC) patients treated with
inhibitors of the PD-1/PD-L1 checkpoint. This includes
robust and durable responses in previously treated pa-
tients with progressive locally advanced or metastatic
NSCLC. However, a large percentage of patients do not
respond to checkpoint inhibitors delivered as single
agents. Studies demonstrate that tumor-inﬁltrating CD8þ
T cells are requisite for antitumor responses to antibody-
mediated therapies that block PD-1 or PD-L1. One po-
tential approach to extend the effectiveness of checkpoint
inhibitors to additional NSCLC patients is to enhance T cell
responses by in situ vaccination that takes advantage of
the full repertoire of available tumor antigens. In pre-
clinical and clinical trials, we discovered that CCL21 has
antitumor properties and CCL21-DC has the capacity to
induce both local T cell recruitment and systemic immune
responses. We hypothesized that in situ vaccination with
CCL21-DC could serve as a tool to restore tumor T cell
inﬁltration, tumor antigen presentation, and T cell
responsiveness, thereby sensitizing non-responsive
NSCLC tumors to checkpoint blockade. To test this hy-
pothesis, we ﬁrst evaluated CCL21-DC as a monotherapy
in the well-characterized syngeneic KRASG12D murine
model of lung cancer. We observed decreased tumor
growth, increased tumor-inﬁltrating lymphocyte (TIL)
cytolytic activity against the autologous tumor, and
increased IFNg/TNFa in the tumor, aswell as systemically
in the spleen. Using the same LKR13 murine model, we
observed that anti-PD-1 monotherapy also inhibited tu-
mor growth, increased TIL cytolytic activity against the
autologous tumor, and increased IFNy/TNFa in the tumor,
as well as systemically in the spleen. To determine if TIL
activity from the CCL21-DC treatment group could beenhanced by PD-1 blockade, we performed an in vitro
cytolytic assay. TIL from the CCL21-DC group had signif-
icantly greater cytolytic activity against the autologous
tumor in the presence of PD-1 antibody relative to control
antibody. We next evaluated intratumoral CCL21 and
intraperitoneal anti-PD-1 administered in combination to
LKR13 tumor-bearing mice. Both monotherapies reduced
ﬁnal tumor volume approximately three-fold, and the
combination proved more efﬁcacious than either agent
alone. We obtained similar results utilizing the syngeneic
3LL murine lung cancer model. Both monotherapies
signiﬁcantly reduced tumor growth, such that the ﬁnal
3LL tumor volume at the time of necropsy was approxi-
mately half that of the control group, and the combination
of checkpoint blockade and CCL21 augmented the anti-
tumor activity nearly two-fold more. Collectively, these
data support the hypothesis that intratumoral adminis-
tration of CCL21-DC and checkpoint blockade therapy
cooperatively inhibit NSCLC tumor growth to a greater
extent than either monotherapy alone. We anticipate that
the capacity of in situ vaccination to drive both DC and T
cell effector inﬁltration of NSCLC tumors will play an
important role in increasing the number of patients
responding to immunotherapy in the future.
Diagnostic and predictive
quantitative-imaging features
in lung cancer screeningMatthew B. Schabath,1 Ying Liu,1 Hua Wang,1
Olya Stringﬁeld,1 YoganandBalagurunathan,1Alberto Garcia,1 Lawrence Hall,2 Dmitry Goldgof,2
Robert J. Gillies1 1H. Lee Mofﬁtt Cancer Center &
Research Institute, Tampa, FL, 2The University of South
Florida, Tampa, FL
Background: Although the National Lung Screening
Trial (NLST) found a 20% reduction for lung cancer
mortality among participants screened with low-dose
computed tomography (LDCT) compared to standard
chest radiography, there are many limitations of LDCT
screening. First, LDCT screening identiﬁes large numbers
of indeterminate pulmonary nodules (IPNs) of which
only a fraction develop into cancer. At present non-
invasive approaches do not exist to determine whether
these IPNs are cancerous or benign. Next, if a nodule is
detected, clinical guidelines provide for the evaluation
and follow-up of nodules, but do not provide clinical
decision tools to predict risk and probability of cancer
development. Cumulatively, these limitations of LDCT
screening critically require development of non-invasive,
accurate quantitative imaging-based classiﬁer models
that i) can be reduce false positives by differentiating
